Detalhe da pesquisa
1.
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas.
Blood;
143(9): 822-832, 2024 Feb 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38048694
2.
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
Haematologica;
2023 Nov 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38031804
3.
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Lancet Oncol;
23(8): 1055-1065, 2022 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35803286
4.
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
Breast Cancer Res Treat;
178(1): 121-133, 2019 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31368034
5.
Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma.
Clin Lymphoma Myeloma Leuk;
24(2): 105-121, 2024 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37981564
6.
Automated Lugano Metabolic Response Assessment in 18F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on 18F-Fluorodeoxyglucose-Positron Emission Tomography.
J Clin Oncol;
: JCO2301978, 2024 Jun 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38843483
7.
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
Nat Med;
30(1): 229-239, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38072960
8.
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.
J Clin Oncol;
: JCO2302329, 2024 Mar 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38547425
9.
Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real-world data in relapsed/refractory follicular lymphoma in third or subsequent lines of systemic therapy.
Leuk Lymphoma;
64(14): 2269-2278, 2023 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37840271
10.
Systems-based digital twins to help characterize clinical dose-response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL.
Clin Transl Sci;
16(7): 1134-1148, 2023 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36908269
11.
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study.
Blood Adv;
7(20): 6055-6065, 2023 10 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37581593
12.
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.
Blood Adv;
7(17): 4926-4935, 2023 09 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37067952
13.
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study.
Lancet Haematol;
9(4): e289-e300, 2022 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35358443
14.
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
J Clin Oncol;
40(5): 481-491, 2022 02 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34914545
15.
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.
Clin Cancer Res;
27(2): 447-459, 2021 01 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33148674
16.
Nontuberculous mycobacteria infections in immunocompromised patients: single institution experience.
J Pediatr Hematol Oncol;
31(8): 556-60, 2009 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19641470
17.
High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cells.
Blood Adv;
3(19): 2825-2835, 2019 10 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31582391
18.
Nodular lymphocyte-predominant Hodgkin lymphoma presenting as fulminant hepatic failure in a pediatric patient: a case report with pathologic, immunophenotypic, and molecular findings.
Appl Immunohistochem Mol Morphol;
16(2): 196-201, 2008 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18227720
19.
SETDB2 Links E2A-PBX1 to Cell-Cycle Dysregulation in Acute Leukemia through CDKN2C Repression.
Cell Rep;
23(4): 1166-1177, 2018 04 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29694893
20.
CBP Modulates Sensitivity to Dasatinib in Pre-BCR+ Acute Lymphoblastic Leukemia.
Cancer Res;
78(22): 6497-6508, 2018 11 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30262461